(Q39441964)

12 September 2017

Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

12 September 2017

1 reference

E J Brandl

1

1 reference

12 September 2017

A K Tiwari

2

1 reference

12 September 2017

X Zhou

3

1 reference

12 September 2017

J Deluce

4

1 reference

12 September 2017

J L Kennedy

5

1 reference

12 September 2017

D J Müller

6

1 reference

12 September 2017

M A Richter

7

1 reference

12 September 2017

language of work or name

1 reference

2 April 2013

1 reference

The Pharmacogenomics Journal

12 September 2017

1 reference

12 September 2017

14

1 reference

12 September 2017

176-181

1 reference

12 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/tpj.2013.12

12 September 2017

0 references

cites work

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Clinical practice. Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Evidence-based pharmacotherapy of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Cerebral activation in children and adolescents with obsessive-compulsive disorder before and after treatment: a functional MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Pharmacogenetics of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Pharmacogenomics of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Genetics and personalized medicine in antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Pharmacogenetics of obsessive-compulsive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Will a new genotyping test help the clinician predict response to antidepressant drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Cytochrome P450 2D6 genotype variation and venlafaxine dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

A prospective study of 86 new patients with social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Association between cytochrome P450 2D6 genotype and harm avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Venlafaxine serum levels and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Is pharmacogenetic CYP2D6 testing useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 in the brain: genotype effects on resting brain perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

CYP2D6 polymorphism in patients with eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.12

21 January 2018

Identifiers

DOI

10.1038/TPJ.2013.12

1 reference

12 September 2017

1 reference